Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 282 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Venous Thromboembolism Clear all

Conditions: Cardiovascular Diseases, Venous Thromboembolism, Atrial Fibrillation, Bleeding, Stroke
Interventions: Clinical Pharmacist Intervention; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Venous Thromboembolism, Pulmonary Embolism, Cancer, Deep Vein Thrombosis, COPD
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 5,451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Interventions: ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.; Device · Drug
Lead sponsor: Inari Medical; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 48
States / cities: Scottsdale, Arizona • Tucson, Arizona • Orange, California + 43 more

Conditions: Pulmonary Embolism and Thrombosis
Interventions: EkoSonic Endovascular System with thrombolytic; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 65
States / cities: Glendale, Arizona • Los Angeles, California • Englewood, Colorado + 54 more

Conditions: Venous Thromboembolism, Pulmonary Embolism, DVT
Interventions: Rivaroxaban, Apixaban; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 120 Years
Enrollment: 41,875 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Venous Thromboembolism
Interventions: Risk calculator; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 90,537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Venous Thromboembolism
Interventions: dalteparin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: Up to 18 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 17
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more

Conditions: Critical Illness, Deep Venous Thrombosis
Interventions: LMWH (Fragmin, dalteparin), Unfractionated Heparin; Drug
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 3,659 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 4
States / cities: Rochester, Minnesota • St Louis, Missouri • Providence, Rhode Island + 1 more

Conditions: Women's Health, Blood Coagulation Disorders
Interventions: Norethindrone; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Symptomatic Venous Thromboembolism (VTE)
Interventions: REGN7508, Acetylsalicylic Acid (ASA), Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 42
States / cities: La Mesa, California • Rancho Mirage, California • Riverside, California + 32 more

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Standard of Care; Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 17 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 23
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Venous Thromboembolism, Cancer, Cardiovascular Events
Interventions: Rosuvastatin, Placebo Drug; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 9
States / cities: Irvine, California • New Haven, Connecticut • Miami, Florida + 4 more

Conditions: Cancer-related Venous Thromboembolism
Interventions: Questionnaires; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
Interventions: Human Alert; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2,496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 26
States / cities: Scottsdale, Arizona • Long Beach, California • Orange, California + 22 more

Conditions: Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases
Interventions: Patient self-management, Usual care provided by anticoagulation providers; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Loma Linda, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more

Conditions: Venous Thromboembolism
Interventions: Insuflon; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis, Renal Vein Thrombosis, Retinal Vein Thrombosis
Interventions: Direct Oral Anticoagulants; Drug
Lead sponsor: University of Malta; Other
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Venous Thromboembolism, Neoplasms
Interventions: Clinical program; Other
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Venous Thromboembolism, Thoracic Surgery, Esophageal Cancer
Interventions: Not listed
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Rochester, Minnesota • Cleveland, Ohio

Conditions: Venous Thromboembolism
Interventions: Not listed
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban, Warfarin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 78,605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Venous Thromboembolism, Pulmonary Embolus, Deep Vein Thrombosis
Interventions: Not listed
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Deep Vein Thrombosis, Pulmonary Embolism
Interventions: The Focus™ Neuromuscular Stimulation System; Device
Lead sponsor: University at Buffalo; Other
Eligibility: 50 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Wounds and Injuries, Venous Thromboembolism
Interventions: Aspirin and Rosuvastatin, Placebo (for Aspirin and Rosuvastatin); Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Search by objective public record fields.

LEAVE Safe With DOACs

Epidemiology of Venous Thromboembolism

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

An International Pulmonary Embolism Registry Using EKOS

Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data

Title: Randomized Trial of an EHR Embedded Risk Calculator vs. Standard VTE Prophylaxis for Medical Patients

Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)

The Effect of the Mini-pill on Blood Factors in Women at Increased Risk for Forming Blood Clots

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

Statins to Prevent Cancer Associated Blood Clots

Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization

Multi-Center Human Alert Trial to Prevent DVT and PE

Warfarin Patient Self-management Implementation in the US Healthcare System

Once Weekly Subcutaneous Ports for the Administration of Anticoagulants

DOAC in Unusual Site Venous Thrombosis

Implementing VTE Prevention in Ambulatory Cancer Care

Incidence of Venous Thromboembolism in Patients Undergoing Major Esophageal Resection

Platelet FcGammaRIIa and Risk of Venous Thromboembolism in Cancer

Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data

Multicenter Registry for Comparative Effectiveness Analysis of Venous Thromboembolism in Trauma Patients

Venous Blood Flow Velocity: Electrical Foot Stimulation Compared to Intermittent Pneumatic Compression of the Foot

STAT-STatin and Aspirin in Trauma